Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albumiuria

Hypertension Research

Volumn 30, Issue 1, 2007, Pages 39-47

  Saito, Fumio ^a   Fujita, Hirotaka ^a   Takahashi, Atsuhiko ^a   Ichiyama, Izumi ^a   Harasawa, Shinsuke ^b   Oiwa, Kouji ^c   Takahashi, Naoyuki ^a   Otsuka, Yuji ^a   Uchiyama, Takashi ^a   Kanmatsuse, Katsuo ^a   Kushiro, Toshio ^a  

^a NIHON UNIVERSITY   (Japan)

^b TOKYO RINKAI HOSPITAL   (Japan)

^c Yokohama Chuou Hospital   (Japan)

Author keywords

Angiotensin receptor blocker; Benidipine; Blood pressure; Renal protection; Urinary albumin excretion

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; LOSARTAN; VALSARTAN;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OPEN STUDY; OPTIMAL DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; URINALYSIS;

AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; COST-BENEFIT ANALYSIS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED;

EID: 33847043872     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.39     Document Type: Article

References (22)

1. Peterson JC, Adler S, Burkart JM, et al: The modification of diet in renal disease study group: blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754-762.
2. Viberti G, Wheeldon MN, for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
3. Lewis JE, Hunsicker GL, Clarke RW, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J M 2001; 345: 851-860.
4. Jafar TH, Stark PC, Schmid CH, et al: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
5. Japanese Society of Hypertension Guidelines Committee: Renal disease and hypertension, in: Guidelines for the Management of Hypertension (JSH 2004). Tokyo, Life Science, 2004, pp 41-44.
6. Chobian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
7. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 11-53.
8. Yue W, Kimura S, Fujisawa Y, et al: Benidipine dilates both pre- and post-glomerular arteriole in the canine kidney. Hypertens Res 2001; 24: 429-436.
9. Hayashi K, Ozawa Y, Saruta T, Epstein M: Renal hemodynamic effects of calcium antagonists, in Epstein M (ed): Calcium Antagonists in Clinical Medicine. New York, Hanley & Belfus, 2001, pp 559-578.
10. 2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005; 45: 241-246.
11. Hansen PB, Jensen BL, Andreasen D, Skøtt O: Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638.
12. Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474.
13. Zeeuw DD: Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int 2004; 66: S2-S6.
14. Wright JT Jr, Bakris G, Greene T, et al: African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: result from the AASK trial. JAMA 2002; 288: 2421-2431.
15. Casas JP, Chua W, Loukogeorgakis S, et al: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
16. Cushman WC, Ford CE, Cutler JA, et al: Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trail (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393-404.
17. Dahlöf B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
18. Garg JP, Elliot WJ, Folker A, Izhar M, Black HR, RUSH University Hypertensive Service: Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18: 619-626.
19. Kawata T, Hashimoto S, Koike T: Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J Cardiovac Pharmacol 1997; 30: 431-436.
20. Kimura K: Effect of benidipine hydrochloride on renal arterioles. Ther Res 1994; 15: 411-414.
21. Yao K, Sato H, Ina Y, Suzuki K, Ohno T, Shirakura S: Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker hypertensive Dahl rats. Hypertens Res 2003; 26: 635-641.
22. Yao K, Sato H, Sonoda R, Ina Y, Suzuki K, Ohno T: Effect of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. Hypertens Res 2003; 26: 569-576.